Boston, Mass.-based but UK-listed PureTech Health PLC says its Vor BioPharma start-up is advancing a novel approach to chimeric antigen receptor (CAR) T-cell therapy that has the potential to broaden the science's applicability and success rate in other cancers – but it's not willing to say exactly how it will do that.
IP Commercializer PureTech Enters CAR-T With Vor BioPharma Start-Up
PureTech Health has moved into the hot area of CAR-T immuno-oncology by launching Vor BioPharma - but the IP commercializer isn't giving details on the start-up's novel chimeric antigen receptor T-cell therapy platform, or how it hopes to remove bottlenecks to the approach's use outside of B-cell cancers.

More from Anticancer
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
More from Therapy Areas
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
The UK giant is forecasting peak sales of $5bn plus